GREENWICH LIFESCIENCES, INC. (GLSI) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
16/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseGLSI / S&P -2.33% / 15.20% |
LoseGLSI / S&P GLSI unavailable / 15.00% |
LoseGLSI / S&P 13.99% / 50.40% |
| 2026-Q11/3 |
WinGLSI / S&P 14.33% / -4.33% |
LoseGLSI / S&P GLSI unavailable / 11.30% |
LoseGLSI / S&P 21.48% / 27.70% |
| 2025-Q41/3 |
WinGLSI / S&P 111.16% / 2.65% |
LoseGLSI / S&P GLSI unavailable / 9.00% |
LoseGLSI / S&P 9.77% / 13.40% |
| 2025-Q32/3 |
WinGLSI / S&P 9.70% / 8.12% |
LoseGLSI / S&P GLSI unavailable / 4.61% |
WinGLSI / S&P 91.25% / 13.45% |
| 2025-Q21/3 |
LoseGLSI / S&P -4.93% / 10.94% |
LoseGLSI / S&P GLSI unavailable / 4.83% |
WinGLSI / S&P 81.01% / 10.63% |
| 2025-Q11/3 |
LoseGLSI / S&P -15.05% / -4.27% |
LoseGLSI / S&P GLSI unavailable / 4.98% |
WinGLSI / S&P 87.50% / 10.57% |
| 2024-Q41/3 |
LoseGLSI / S&P -21.85% / 2.41% |
LoseGLSI / S&P GLSI unavailable / 5.25% |
WinGLSI / S&P 90.00% / 6.15% |
| 2024-Q31/3 |
LoseGLSI / S&P -16.74% / 5.89% |
LoseGLSI / S&P GLSI unavailable / 5.89% |
WinGLSI / S&P 12.68% / 6.11% |
| 2024-Q21/3 |
LoseGLSI / S&P -13.44% / 4.28% |
LoseGLSI / S&P GLSI unavailable / 5.38% |
WinGLSI / S&P 12.86% / 5.12% |
| 2024-Q12/3 |
WinGLSI / S&P 89.54% / 10.56% |
LoseGLSI / S&P GLSI unavailable / 5.71% |
WinGLSI / S&P 14.29% / 5.59% |
| 2023-Q41/3 |
WinGLSI / S&P 19.00% / 11.69% |
LoseGLSI / S&P GLSI unavailable / 6.81% |
LoseGLSI / S&P GLSI unavailable / 7.78% |
| 2023-Q30/3 |
LoseGLSI / S&P -8.35% / -3.27% |
LoseGLSI / S&P GLSI unavailable / 7.52% |
LoseGLSI / S&P GLSI unavailable / -5.03% |
| 2023-Q20/3 |
LoseGLSI / S&P -30.06% / 8.74% |
LoseGLSI / S&P GLSI unavailable / 9.50% |
LoseGLSI / S&P GLSI unavailable / -8.57% |
| 2023-Q10/3 |
LoseGLSI / S&P -9.28% / 7.50% |
LoseGLSI / S&P GLSI unavailable / 10.77% |
LoseGLSI / S&P GLSI unavailable / -15.69% |
| 2022-Q41/3 |
WinGLSI / S&P 67.03% / 7.56% |
LoseGLSI / S&P GLSI unavailable / 11.88% |
LoseGLSI / S&P GLSI unavailable / -17.99% |
| 2022-Q31/3 |
WinGLSI / S&P 7.44% / -4.88% |
LoseGLSI / S&P GLSI unavailable / 13.47% |
LoseGLSI / S&P GLSI unavailable / -1.41% |
| 2022-Q20/3 |
LoseGLSI / S&P -56.83% / -16.10% |
LoseGLSI / S&P GLSI unavailable / 13.71% |
LoseGLSI / S&P GLSI unavailable / 11.04% |
| 2022-Q10/3 |
LoseGLSI / S&P -19.36% / -4.60% |
LoseGLSI / S&P GLSI unavailable / 15.97% |
LoseGLSI / S&P GLSI unavailable / 42.23% |
| 2021-Q40/3 |
LoseGLSI / S&P -37.73% / 11.03% |
LoseGLSI / S&P GLSI unavailable / 15.00% |
LoseGLSI / S&P GLSI unavailable / 96.40% |
| 2021-Q30/3 |
LoseGLSI / S&P -13.06% / 0.58% |
LoseGLSI / S&P GLSI unavailable / 10.77% |
LoseGLSI / S&P GLSI unavailable / 69.42% |
| 2021-Q21/3 |
WinGLSI / S&P 31.83% / 8.55% |
LoseGLSI / S&P GLSI unavailable / 6.58% |
LoseGLSI / S&P GLSI unavailable / 51.81% |
| 2021-Q10/3 |
LoseGLSI / S&P -6.53% / 6.17% |
LoseGLSI / S&P GLSI unavailable / -1.06% |
LoseGLSI / S&P GLSI unavailable / 7.39% |
| 2020-Q41/3 |
WinGLSI / S&P 692.83% / 12.15% |
LoseGLSI / S&P GLSI unavailable / -3.72% |
LoseGLSI / S&P GLSI unavailable / -33.42% |
| 2020-Q30/3 |
LoseGLSI / S&P GLSI unavailable / 8.93% |
LoseGLSI / S&P GLSI unavailable / -2.04% |
LoseGLSI / S&P GLSI unavailable / -27.10% |
| 2020-Q20/3 |
LoseGLSI / S&P GLSI unavailable / 20.54% |
LoseGLSI / S&P GLSI unavailable / -0.46% |
LoseGLSI / S&P GLSI unavailable / -27.11% |
| 2020-Q10/3 |
LoseGLSI / S&P GLSI unavailable / -19.60% |
LoseGLSI / S&P GLSI unavailable / 3.47% |
LoseGLSI / S&P GLSI unavailable / -14.75% |
| 2019-Q40/3 |
LoseGLSI / S&P GLSI unavailable / 9.07% |
LoseGLSI / S&P GLSI unavailable / 5.36% |
LoseGLSI / S&P GLSI unavailable / 2.99% |
| 2019-Q30/3 |
LoseGLSI / S&P GLSI unavailable / 1.70% |
LoseGLSI / S&P GLSI unavailable / 5.02% |
LoseGLSI / S&P GLSI unavailable / 0.21% |
| 2019-Q20/3 |
LoseGLSI / S&P GLSI unavailable / 4.30% |
LoseGLSI / S&P GLSI unavailable / 6.64% |
LoseGLSI / S&P GLSI unavailable / 8.65% |
| 2019-Q10/3 |
LoseGLSI / S&P GLSI unavailable / 13.65% |
LoseGLSI / S&P GLSI unavailable / 8.12% |
LoseGLSI / S&P GLSI unavailable / 14.29% |
| 2018-Q40/3 |
LoseGLSI / S&P GLSI unavailable / -13.52% |
LoseGLSI / S&P GLSI unavailable / 9.05% |
LoseGLSI / S&P GLSI unavailable / 18.23% |
| 2018-Q30/3 |
LoseGLSI / S&P GLSI unavailable / 7.71% |
LoseGLSI / S&P GLSI unavailable / 10.21% |
LoseGLSI / S&P GLSI unavailable / 19.06% |
| 2018-Q20/3 |
LoseGLSI / S&P GLSI unavailable / 3.43% |
LoseGLSI / S&P GLSI unavailable / 9.03% |
LoseGLSI / S&P GLSI unavailable / 14.46% |
| 2018-Q10/3 |
LoseGLSI / S&P GLSI unavailable / -0.76% |
LoseGLSI / S&P GLSI unavailable / 7.68% |
LoseGLSI / S&P GLSI unavailable / 12.46% |
| 2017-Q40/3 |
LoseGLSI / S&P GLSI unavailable / 6.64% |
LoseGLSI / S&P GLSI unavailable / 7.03% |
LoseGLSI / S&P GLSI unavailable / 13.82% |
| 2017-Q30/3 |
LoseGLSI / S&P GLSI unavailable / 4.48% |
LoseGLSI / S&P GLSI unavailable / 5.68% |
LoseGLSI / S&P GLSI unavailable / 17.57% |
| 2017-Q20/3 |
LoseGLSI / S&P GLSI unavailable / 3.09% |
LoseGLSI / S&P GLSI unavailable / 4.83% |
LoseGLSI / S&P GLSI unavailable / 17.74% |
| 2017-Q10/3 |
LoseGLSI / S&P GLSI unavailable / 6.07% |
LoseGLSI / S&P GLSI unavailable / 3.67% |
LoseGLSI / S&P GLSI unavailable / 13.32% |
| 2016-Q40/3 |
LoseGLSI / S&P GLSI unavailable / 3.82% |
LoseGLSI / S&P GLSI unavailable / 2.09% |
LoseGLSI / S&P GLSI unavailable / 7.05% |
| 2016-Q30/3 |
LoseGLSI / S&P GLSI unavailable / 3.85% |
LoseGLSI / S&P GLSI unavailable / 0.20% |
LoseGLSI / S&P GLSI unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | GLSI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 63.15% | 20.78% |
| Annualized return | 63.15% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | GLSI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -57.19% | 83.14% |
| Annualized return | -15.61% | 12.86% |
10Y · 2020-09-25 to 2026-08-27
| Metric | GLSI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 274.60% | 319.30% |
| Annualized return | 14.12% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |